Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
Conditions
Interventions
AK002
Placebo
Locations
21
United States
Phoenician Centers for Research and Innovation
Phoenix, Arizona, United States
Mayo Clinic
Scottsdale, Arizona, United States
Ventura Clinical Trials
Ventura, California, United States
UC Denver
Aurora, Colorado, United States
Riverside Clinical Research
Edgewater, Florida, United States
Advanced Research Institute
New Port Richey, Florida, United States
Start Date
July 18, 2018
Primary Completion Date
June 24, 2019
Completion Date
June 24, 2019
Last Updated
January 19, 2024
NCT05229432
NCT05199532
NCT05214768
NCT05439772
NCT05251909
NCT03664960
Lead Sponsor
Allakos Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions